drugset
drugset / Trial / NCT01380743

Drug-drug Interaction Study

NCT01380743 ↗

Phase 2 Completed 25 enrolled Amicus Therapeutics
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study evaluates drug-drug interactions between AT2220 (duvoglustat) and recombinant human alpha-glucosidase (rhGAA, also known as alglucosidase alfa) in participants with Pompe Disease.

Timeline

Start
2011-10-31
Primary completion
2013-01-04
Completion
2013-01-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Duvoglustat Small molecule 50 mg Oral
Subject Duvoglustat Small molecule 100 mg Oral
Subject Duvoglustat Small molecule 250 mg Oral
Subject Duvoglustat Small molecule 600 mg Oral
Background alglucosidase alfa Protein / enzyme biologic — Intravenous

Indications

glycogen storage disease II